Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
RE Clark, IA Dodi, SC Hill, JR Lill… - Blood, The Journal …, 2001 - ashpublications.org
The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML).
Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA …
Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA …
Dendritic cells and immunotherapy for malignant disease.
CDL Reid - British Journal of Haematology, 2001 - search.ebscohost.com
Rejev Page 1 British Journal of Haematology, 2001, 112, 874–887 Rejev DENDRITIC (CEI, IS
AND IMMUNOTHERAPY F()R MALIGNANT DISEASE In the last few years, a number of factors …
AND IMMUNOTHERAPY F()R MALIGNANT DISEASE In the last few years, a number of factors …
Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
M Matsushita, H Ikeda, M Kizaki… - British journal of …, 2001 - Wiley Online Library
PRAME (Preferentially expressed antigen of melanoma) has been previously identified as a
melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a …
melanoma antigen recognized by cytotoxic T cells (CTLs) and found to be expressed in a …
Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine
RJ Orentas, D Schauer, Q Bin, BD Johnson - Cellular immunology, 2001 - Elsevier
The absence of surface costimulatory molecules explains in part the lack of an effective anti-
tumor immune response in tumor-bearing animals, even though unique tumor antigens may …
tumor immune response in tumor-bearing animals, even though unique tumor antigens may …
HLA class II–restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia–derived dendritic cells to CD4+ T lymphocytes
M Yasukawa, H Ohminami, K Kojima… - Blood, The Journal …, 2001 - ashpublications.org
Bcr-abl fusion peptide–specific CD4+ T-lymphocyte clones have recently been shown to
augment colony formation by chronic myelogenous leukemia (CML) cells in a bcr-abl type …
augment colony formation by chronic myelogenous leukemia (CML) cells in a bcr-abl type …
BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia
RE Clark, SE Christmas - Leukemia & Lymphoma, 2001 - Taylor & Francis
The BCR-ABL gene that arises in chronic myeloid leukaemia (CML) is a neoantigen.
Peptides derived from the BCR-ABL fusion junction may therefore be immunogenic, if …
Peptides derived from the BCR-ABL fusion junction may therefore be immunogenic, if …
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl -positive leukemia in mice
L He, H Feng, A Raymond, M Kreeger, Y Zeng… - Cancer Immunology …, 2001 - Springer
Chronic myelogenous leukemia (CML) is a clonal disorder characterized by proliferation of
cells that possess the bcr-abl fusion gene resulting in the production of one of two possible …
cells that possess the bcr-abl fusion gene resulting in the production of one of two possible …
Dendritic cells in patients with non‐progressive B‐chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern
MR Rezvany, M Jeddi‐Tehrani… - British journal of …, 2001 - Wiley Online Library
Dendritic cells (DC) are attractive candidates for use in vaccine‐based immunotherapy. We
have analysed the functional capability of DC generated in vitro from blood CD14+ cells of …
have analysed the functional capability of DC generated in vitro from blood CD14+ cells of …
Tumour immunotherapy: new tools, new treatment modalities and new T‐cell antigens
JL Schultze, B Maecker… - Vox …, 2001 - Wiley Online Library
Tumour immunology has seen many exciting developments in the last few years. In addition
to tumour antigens that are defined by antitumour T‐and B‐cell responses in patients, the …
to tumour antigens that are defined by antitumour T‐and B‐cell responses in patients, the …
A CD4+ T CELL CLONE SELECTED FROM A CML PATIENT AFTER DONOR LYMPHOCYTE INFUSION RECOGNIZES BCR-ABL BREAKPOINT PEPTIDES BUT …
Background. In patients with chronic myelocytic leukemia (CML), the breakpoint cluster
region and fusion between the BCR and the c-ABL genes (BCR-ABL) oncogen product is a …
region and fusion between the BCR and the c-ABL genes (BCR-ABL) oncogen product is a …